Funder
Natural Science Foundation of Beijing Municipality
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference43 articles.
1. Cohen MH, Williams G, Johnson JR et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(5):935–942
2. García-Ferrer M, Wojnicz A, Mejía G, Koller D, Abad-Santos F (2019) Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther 41(12):22
3. Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984
4. Deininger MW, Shah NP, Altman JK et al (2020) Chronic myeloid leukemia, version 22021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(10):1385–1415
5. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879–894
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献